CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

por Lefort, S, Thuleau, A, Kieffer, Y, Sirven, P, Bieche, I, Marangoni, E, Vincent-Salomon, A, Mechta-Grigoriou, F
Publicado 2017